Unraveling Cannabidiol's Dual Modulatory Role in Schizophrenia: Network Pharmacology and In Vivo Validation of Neuroinflammatory and Behavioral Modulation
Ying Wei, Xiang Liu, Shijun Lin, Zhiwei Jia, Lin Liu, Baiqiang Wang, Linchuan Liao, Xue Mei · 2025
Read Unraveling Cannabidiol's Dual Modulatory Role in Schizophrenia: Network Pharmacology and In Vivo Validation of Neuroinflammatory and Behavioral Modulation by Ying Wei, Xiang Liu, Shijun Lin, Zhiwei Jia, Lin Liu, Baiqiang Wang, Linchuan Liao, Xue Mei (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12696127.txt.
Description
Ying Wei and co-authors study whether cannabidiol, a non-intoxicating compound from cannabis, could help in schizophrenia, in a 2025 study. Current drugs for the illness have limited effect and strong side effects. The team first used network methods to predict which targets and paths the compound might act on, with brain inflammation a key lead.
Cell tests showed the compound lowered several inflammatory signals and shifted a serotonin-linked path. In an animal model of schizophrenia-like behaviour, five days of treatment eased anxiety in maze tests, improved spatial memory, and improved social behaviour. Inflammatory signals fell in both blood and brain, and lower brain signals tracked better behaviour. The authors stress that human trials are still needed before any clinical claim can be made.
Catalog record
| CREATOR | Ying Wei, Xiang Liu, Shijun Lin, Zhiwei Jia, Lin Liu, Baiqiang Wang, Linchuan Liao, Xue Mei |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 68 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |